Research
Hormonal
1 kg/m² lower BMI via the GIP/GIPR score is associated with 43% lower risk of heart failure.
Targeting GIP receptor pathways may significantly reduce heart failure risk.
StrongSupportsmedium confidence
In one-sample MR analyses, 1 kg/m² lower BMI via the GIP/GIPR score was associated with 43% lower risk of heart failure (P = 5 × 10⁻⁵).
Why this rating
Based on large sample size and Mendelian randomization analysis.
Source
Genetic variants of glucose-dependent insulinotropic polypeptide (GIP) signalling as proxy for body weight reduction and cardiovascular risk
Frida Emanuelsson et al. · European Heart Journal · 2025
DOI 10.1093/eurheartj/ehaf779
other · n=408056Cited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- 1 kg/m² lower BMI via the GIP/GIPR score is associated with 29% lower risk of major adverse cardiovascular events (MACE).Strong
- Genetic proxies for body weight reduction via GIP receptor targeting reduces the risk of MACE and heart failure, mediated partly through lower BMI and partly through lower HbA1c.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →